vs

Side-by-side financial comparison of ESSENTIAL PROPERTIES REALTY TRUST, INC. (EPRT) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $158.8M, roughly 1.3× ESSENTIAL PROPERTIES REALTY TRUST, INC.). ESSENTIAL PROPERTIES REALTY TRUST, INC. runs the higher net margin — 37.8% vs -62.0%, a 99.8% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 22.8%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 20.6%).

Essential Properties Realty Trust is a publicly traded real estate investment trust (REIT) that acquires, owns and manages a diversified portfolio of single-tenant net-leased commercial properties across the United States. Its assets primarily cover essential service-oriented sectors including casual dining, automotive services, medical clinics, early childhood education centers and light industrial facilities, with tenants mostly holding robust long-term operating track records.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

EPRT vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.3× larger
RARE
$207.3M
$158.8M
EPRT
Growing faster (revenue YoY)
RARE
RARE
+3.1% gap
RARE
25.9%
22.8%
EPRT
Higher net margin
EPRT
EPRT
99.8% more per $
EPRT
37.8%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
20.6%
EPRT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EPRT
EPRT
RARE
RARE
Revenue
$158.8M
$207.3M
Net Profit
$60.0M
$-128.6M
Gross Margin
Operating Margin
56.5%
-54.7%
Net Margin
37.8%
-62.0%
Revenue YoY
22.8%
25.9%
Net Profit YoY
6.5%
3.5%
EPS (diluted)
$0.28
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPRT
EPRT
RARE
RARE
Q1 26
$158.8M
Q4 25
$149.9M
$207.3M
Q3 25
$144.9M
$159.9M
Q2 25
$137.1M
$166.5M
Q1 25
$129.4M
$139.3M
Q4 24
$119.7M
$164.6M
Q3 24
$117.1M
$139.5M
Q2 24
$109.3M
$147.0M
Net Profit
EPRT
EPRT
RARE
RARE
Q1 26
$60.0M
Q4 25
$68.1M
$-128.6M
Q3 25
$65.6M
$-180.4M
Q2 25
$63.2M
$-115.0M
Q1 25
$56.1M
$-151.1M
Q4 24
$55.4M
$-133.2M
Q3 24
$49.1M
$-133.5M
Q2 24
$51.5M
$-131.6M
Operating Margin
EPRT
EPRT
RARE
RARE
Q1 26
56.5%
Q4 25
65.9%
-54.7%
Q3 25
64.7%
-106.9%
Q2 25
64.1%
-64.8%
Q1 25
61.6%
-102.6%
Q4 24
66.1%
-74.3%
Q3 24
59.7%
-94.6%
Q2 24
61.1%
-79.1%
Net Margin
EPRT
EPRT
RARE
RARE
Q1 26
37.8%
Q4 25
45.4%
-62.0%
Q3 25
45.3%
-112.8%
Q2 25
46.1%
-69.0%
Q1 25
43.4%
-108.5%
Q4 24
46.3%
-80.9%
Q3 24
42.0%
-95.7%
Q2 24
47.1%
-89.5%
EPS (diluted)
EPRT
EPRT
RARE
RARE
Q1 26
$0.28
Q4 25
$0.34
$-1.28
Q3 25
$0.33
$-1.81
Q2 25
$0.32
$-1.17
Q1 25
$0.29
$-1.57
Q4 24
$0.31
$-1.34
Q3 24
$0.27
$-1.40
Q2 24
$0.29
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPRT
EPRT
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$15.2M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.4B
$-80.0M
Total Assets
$7.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPRT
EPRT
RARE
RARE
Q1 26
$15.2M
Q4 25
$60.2M
$421.0M
Q3 25
$23.8M
$202.5M
Q2 25
$20.8M
$176.3M
Q1 25
$47.0M
$127.1M
Q4 24
$40.7M
$174.0M
Q3 24
$32.7M
$150.6M
Q2 24
$23.6M
$480.7M
Total Debt
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
$2.5B
Q3 25
$2.6B
Q2 25
$2.3B
Q1 25
$2.1B
Q4 24
$2.1B
Q3 24
$2.2B
Q2 24
$1.9B
Stockholders' Equity
EPRT
EPRT
RARE
RARE
Q1 26
$4.4B
Q4 25
$4.2B
$-80.0M
Q3 25
$3.8B
$9.2M
Q2 25
$3.8B
$151.3M
Q1 25
$3.8B
$144.2M
Q4 24
$3.6B
$255.0M
Q3 24
$3.2B
$346.8M
Q2 24
$3.2B
$432.4M
Total Assets
EPRT
EPRT
RARE
RARE
Q1 26
$7.2B
Q4 25
$6.9B
$1.5B
Q3 25
$6.6B
$1.2B
Q2 25
$6.3B
$1.3B
Q1 25
$6.1B
$1.3B
Q4 24
$5.8B
$1.5B
Q3 24
$5.5B
$1.5B
Q2 24
$5.3B
$1.6B
Debt / Equity
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
0.60×
Q3 25
0.69×
Q2 25
0.61×
Q1 25
0.56×
Q4 24
0.60×
Q3 24
0.69×
Q2 24
0.59×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPRT
EPRT
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
$381.1M
$-99.8M
Q3 25
$99.0M
$-91.4M
Q2 25
$99.8M
$-108.3M
Q1 25
$77.2M
$-166.5M
Q4 24
$308.5M
$-79.3M
Q3 24
$73.5M
$-67.0M
Q2 24
$81.1M
$-77.0M
Free Cash Flow
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
FCF Margin
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Capex Intensity
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Cash Conversion
EPRT
EPRT
RARE
RARE
Q1 26
Q4 25
5.60×
Q3 25
1.51×
Q2 25
1.58×
Q1 25
1.38×
Q4 24
5.57×
Q3 24
1.50×
Q2 24
1.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPRT
EPRT

Rental revenue 1,2$149.4M94%
Other$8.6M5%
Other revenue$779.0K0%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons